Mohammed Khurshed received his M.D. as well as his MSc in Medical Biology/Oncology from University of Amsterdam and is currently enrolled in a PhD program in Dr. Ron van Noorden’s laboratory. In his multidisciplinary career, his ambition is to perform translational research, bringing lab and clinic together. His PhD research project focuses on tumor metabolism, in particular investigating the metabolic rewiring in IDH-mutated glioma for possible Achilles heel as a therapeutic target in the altered metabolism. One of his approaches to unravel tumor metabolism is quantitative enzyme histochemistry and cytochemistry (also called metabolic mapping), which is the preferred method to study enzyme activity in situ that facilitates both the location of enzyme activity as well as robust quantification of enzyme activity within a cell or tissue compartment. To create insights in therapeutic targets, he correlates gene expression profiles, enzyme activity and metabolite levels in tumor metabolism. On the basis of these insights, he performs clinical trial in which patients with IDH1-mutation chondrosarcoma, glioma and cholangiocarcinoma are treated with a combination of metformin and chloroquine, targeting the metabolism. In the long-term, he aims to exploit insights in the mechanism of metabolism and therapy sensitization to develop novel targeted therapies.